Targeting METex14 (NOT publish)
Pedimos desculpa, neste momento não é possível processar o seu registo.
Pedimos desculpa, não está autorizado a aceder a este site. Por favor, contacte a Merck para mais informações.
Necessita registar-se para ter acesso a esta página. Por favor, introduza os dados da sua conta ou registe-se.

Entrar no site Merck
{* #signInForm *}
{* signInEmailAddress *}
{* currentPassword *}
{* captcha *}
{* /signInForm *}

Once you see…

…the importance of targeting METex14 skipping, you can’t ignore it

MET alterations and your NSCLC patients MET alterations and your NSCLC patients

MET alterations and your NSCLC patients

<8

months is the median OS of METex14 skipping NSCLC patients without treatment with MET inhibitor therapy

>24

months is the median OS of METex14 skipping NSCLC patients following treatment with MET inhibitor therapy

1

MET inhibitors are highly specific and offer fewer off-target effects compared to other MET inhibitors

The recent discovery of METex14 skipping as a targetable driver in NSCLC isopening a new chapter in personalized medicine

The success of small molecules in the treatment of cancer have proven that identification of a correct target in cancer patients is crucial for the success of therapy. [Hoelder 2012] Until recently, clinical trials have demonstrated little progress in MET inhibition for NSCLC patients due to lack of appropriately identified patients. [Seimann 2018] The identification of patients harboring primary oncogenic drivers like MET could facilitate personalized medicine, allowing for optimal management of your patients’ health. [NHS 2019]

Identifying the most effective MET inhibitor could unlock enhanced precision in targeted therapy for your patients

There are two subtypes of type I inhibitors; type Ia and type Ib:

  • Type Ib inhibitors are highly specific for MET with fewer off target effects compared to type Ia inhibitors [Reungwetwattana 2017]
  • Type Ib MET inhibitors bind to the MET tyrosine kinase receptor, increasing selectivity, and are among the most effective MET inhibitors [Bladt 2013][Wu 2017]
  • Additionally, type Ib MET inhibitors offer enhanced potency and sustained inhibition when compared to type Ia inhibitors [Bladt 2013][Wu 2017]

MET inhibitor therapy unlocks meaningful overall survival. What would this mean for your patients?

Although there have been many treatment advancements in NSCLC, there remains a significant urgent unmet need for patients with METex14 skipping NSCLC. [Awad 2019][Wolf 2018][Sabari 2018] 

NSCLC patients harboring METex14 skipping demonstrate a poor response to standard of care, such as chemotherapy and immune checkpoint inhibitors. [Awad 2019] 


In an analysis of patients with MET-altered NSCLC treated with MET inhibitor therapy vs. those treated with chemotherapy, patients receiving MET inhibitor therapy demonstrated a median OS of greater than 2 years compared to just 8 months with chemotherapy.  [

8.1

months is the median OS of METex14 skipping NSCLC patients treated with chemotherapy

24.6

months is the median OS of METex14 skipping NSCLC patients following treatment with MET inhibitor therapy

MET-altered NSCLC patients demonstrate a median OS of greater than 2 years following treatment with MET inhibitor therapy when compared to just 8 months in those who receivedxxxx MET-altered NSCLC patients demonstrate a median OS of greater than 2 years following treatment with MET inhibitor therapy when compared to just 8 months in those who receivedxxxx

Additionally, data demonstrates that even in NSCLC patients with concomitant METex14 skipping and high PD-L1 expression, the efficacy of immunotherapy remains poor.


In a retrospective analysis of NSCLC patients with METex14 skipping (n=11/24 with PD-L1 ≥50%), ORR was just 17% and median PFS just 1.9 months following treatment with single or combination immunotherapy. [Sabari 2018]

REFERENCES AND ABBREVIATIONS

Leaving website.

This link will take you to a website to which our Privacy Policy and Conditions may not apply. Merck has no control over the contents and policies of third party sites or resources, and accepts no responsibility for them or for any loss or damage that may arise from your use of them. 

 

 

 

Please check Privacy Policy and Conditions of the linked website.

 

 

 

Do you wish to continue and leave this site?

É um profissional de saúde?

Este website tem como objetivo educar e informar os profissionais de saúde sobre CPNPC.

SIM

    

 

NÃO

Não é um profissional de saúde? Visite o nosso website público.

Continuar